|
176 Companies |
|
232 Products |
|
232 Products |
|
108 Mechanisms of Action |
|
9 Trials |
|
1978 News |
|
| «12...7891011121314151617...4142» |
- LOP628 / Novartis
Enrollment change, Trial termination, Trial primary completion date: Phase 1 Study of LOP628 in Adult Patients With cKit-positive Solid Tumors and Acute Myeloid Leukemia (clinicaltrials.gov) - Sep 29, 2015
P1, N=3, Terminated, Sponsor: Novartis Pharmaceuticals
N=110 --> 3 | Suspended --> Terminated | Trial primary completion date: Jun 2020 --> Mar 2015
- alisertib (MLN8237) / Puma
Trial primary completion date, Combination therapy: Alisertib for Acute Myeloid Leukemia (clinicaltrials.gov) - Sep 24, 2015
P1, N=24, Active, not recruiting, Sponsor: Massachusetts General Hospital
N=110 --> 3 | Suspended --> Terminated | Trial primary completion date: Jun 2020 --> Mar 2015 Trial primary completion date: Apr 2015 --> Dec 2015
- busulfan / Generic mfg., clofarabine / Generic mfg.
Trial primary completion date: Busulfan/Clofarabine + Allogeneic Stem Cell Transplantation (clinicaltrials.gov) - Sep 24, 2015
P2, N=34, Active, not recruiting, Sponsor: Massachusetts General Hospital
Trial primary completion date: Apr 2015 --> Dec 2015 Trial primary completion date: Aug 2015 --> Aug 2016
- Zolinza (vorinostat) / Merck (MSD)
Trial primary completion date: Phase I/II Study of Combination of Sorafenib, Vorinostat, and Bortezomib for the Treatment of Acute Myeloid Leukemia With Complex- or Poor-risk (Monosomy 5/7) Cytogenetics or FLT3-ITD Positive Genotype (clinicaltrials.gov) - Sep 24, 2015
P1/2, N=38, Recruiting, Sponsor: Hamid Sayar
Trial primary completion date: Aug 2015 --> Aug 2016 Trial primary completion date: Feb 2015 --> Feb 2016
- | azacitidine / Generic mfg.
Trial termination, Trial primary completion date: Azacitidine Compared to Conventional Chemotherapy as Consolidation of Elderly Patients With AML (clinicaltrials.gov) - Sep 22, 2015
P2, N=130, Terminated, Sponsor: Karolinska University Hospital
Trial primary completion date: Feb 2015 --> Feb 2016 Not yet recruiting --> Terminated | Trial primary completion date: Mar 2015 --> Sep 2015; Poor recruitment
- | Ovastat (treosulfan) / Medac, Medexus
Trial completion, Trial primary completion date: Treosulfan/Fludarabine/Low Dose TBI as a Preparative Regimen for Children With AML/MDS Undergoing Allo HCT (clinicaltrials.gov) - Sep 16, 2015
P2, N=40, Completed, Sponsor: Center for International Blood and Marrow Transplant Research
Not yet recruiting --> Terminated | Trial primary completion date: Mar 2015 --> Sep 2015; Poor recruitment Active, not recruiting --> Completed | Trial primary completion date: Feb 2017 --> Aug 2015
- | Mylotarg (gemtuzumab ozogamicin) / UCB, PDL, Pfizer
Trial completion, Enrollment change, Trial primary completion date: Combination 5-azacitidine and Gemtuzumab Ozogamicin Therapy for Treatment of Relapsed Acute Myeloid Leukemia (AML) (clinicaltrials.gov) - Sep 14, 2015
P1/2, N=50, Completed, Sponsor: University of California, San Diego
Active, not recruiting --> Completed | Trial primary completion date: Feb 2017 --> Aug 2015 Active, not recruiting --> Completed | N=36 --> 50 | Trial primary completion date: Aug 2014 --> Jun 2015
- | lenalidomide / Generic mfg., azacitidine / Generic mfg.
Trial completion: Azacitidine and Lenalidomide for Acute Myeloid Leukemia (clinicaltrials.gov) - Sep 8, 2015
P1/2, N=31, Completed, Sponsor: Washington University School of Medicine
Active, not recruiting --> Completed | N=36 --> 50 | Trial primary completion date: Aug 2014 --> Jun 2015 Active, not recruiting --> Completed
- Enrollment open: Observational Trial of a Therapeutic Platelet Transfusion Regimen (clinicaltrials.gov) - Sep 8, 2015
P4, N=120, Recruiting, Sponsor: Klinikum N
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- lenalidomide / Generic mfg.
Trial primary completion date: Trial of High Dose Lenalidomide in Patients With MDS and AML With Trilineage Dysplasia (clinicaltrials.gov) - Sep 4, 2015
P2, N=48, Active, not recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Not yet recruiting --> Recruiting Trial primary completion date: Sep 2015 --> Dec 2015
- || pinometostat (EPZ-5676) / Ipsen
Enrollment closed, Trial primary completion date, Metastases: A Phase 1, Open-Label, Dose-Escalation & Expanded Cohort, Continuous IV Infusion, Multi-center Study of the Safety, Tolerability,PK & PD of EPZ-5676 in Treatment Relapsed/Refractory Patients With Leukemias Involving (clinicaltrials.gov) - Sep 4, 2015
P1, N=60, Active, not recruiting, Sponsor: Epizyme, Inc.
Trial primary completion date: Sep 2015 --> Dec 2015 Recruiting --> Active, not recruiting | Trial primary completion date: May 2015 --> Nov 2015
- Campath (alemtuzumab) / Sanofi
Trial completion, Trial primary completion date: T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies (clinicaltrials.gov) - Sep 4, 2015
P2, N=204, Completed, Sponsor: University of Chicago
Recruiting --> Active, not recruiting | Trial primary completion date: May 2015 --> Nov 2015 Active, not recruiting --> Completed | Trial primary completion date: Dec 2013 --> Dec 2014
- fludarabine IV / Generic mfg., mycophenolate mofetil / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date, Combination therapy, IO biomarker, Post-transplantation: Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer (clinicaltrials.gov) - Sep 1, 2015
P=N/A, N=5, Completed, Sponsor: Fred Hutchinson Cancer Research Center
Active, not recruiting --> Completed | Trial primary completion date: Dec 2013 --> Dec 2014 Recruiting --> Completed | N=20 --> 5 | Trial primary completion date: Dec 2015 --> Nov 2014
- bupropion / Generic mfg.
Trial completion: Bupropion in Helping Adults Stop Smoking (clinicaltrials.gov) - Aug 28, 2015
P2, N=97, Completed, Sponsor: Roswell Park Cancer Institute
Recruiting --> Completed | N=20 --> 5 | Trial primary completion date: Dec 2015 --> Nov 2014 Active, not recruiting --> Completed
- decitabine / Generic mfg.
Trial primary completion date: Decitabine as Maintenance Therapy After Standard Therapy in Treating Patients With Previously Untreated Acute Myeloid Leukemia (clinicaltrials.gov) - Aug 27, 2015
P2, N=546, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Trial primary completion date: Jan 2013 --> Jan 2011
- GSK2130579A / GSK
Enrollment change, Trial primary completion date: Evaluation of a New Anti-cancer Immunotherapy in Adult Acute Myeloid Leukemia Patients With a Suboptimal Clinical Response to Induction Chemotherapy (clinicaltrials.gov) - Aug 26, 2015
P1, N=17, Active, not recruiting, Sponsor: GlaxoSmithKline
Trial primary completion date: Jan 2013 --> Jan 2011 N=40 --> 17 | Trial primary completion date: Sep 2018 --> Aug 2017
- lenalidomide / Generic mfg.
Enrollment closed: Trial of High Dose Lenalidomide in Patients With MDS and AML With Trilineage Dysplasia (clinicaltrials.gov) - Aug 25, 2015
P2, N=48, Active, not recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
N=40 --> 17 | Trial primary completion date: Sep 2018 --> Aug 2017 Recruiting --> Active, not recruiting
- fludarabine IV / Generic mfg., cyclophosphamide / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date: Fludarabine, Cyclophosphamide, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer (clinicaltrials.gov) - Aug 24, 2015
P2, N=210, Completed, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Recruiting --> Active, not recruiting Active, not recruiting --> Completed | N=100 --> 210 | Trial primary completion date: Dec 2015 --> Jan 2015
- | daunorubicin / Generic mfg., cytarabine / Generic mfg.
Enrollment change: FAMYLY: Pilot Study Efficacy and Tolerance Fish Oil Emulsion Daunorubicin and Cytarabine Treatment of AML Younger Patients (clinicaltrials.gov) - Aug 21, 2015
P2, N=21, Recruiting, Sponsor: Groupe Ouest Est d'Etude des Leuc
Active, not recruiting --> Completed | N=100 --> 210 | Trial primary completion date: Dec 2015 --> Jan 2015 N=30 --> 21
- plerixafor / Generic mfg.
Enrollment change, Trial termination, Combination therapy: Primal study: Study in Plerixafor and Granulocyte-colony Stimulating Factor Patients With Relapse Acute Myeloid Leukemia (clinicaltrials.gov) - Aug 21, 2015
P1, N=11, Terminated, Sponsor: Groupe Ouest Est d'Etude des Leuc
N=30 --> 21 N=24 --> 11 | Recruiting --> Terminated; no recruitment on time
- Trial termination: Azacitidine, Mitoxantrone Hydrochloride, and Etoposide in Treating Older Patients With Poor-Prognosis Acute Myeloid Leukemia (clinicaltrials.gov) - Aug 20, 2015
P1, N=13, Terminated, Sponsor: National Cancer Institute (NCI)
N=24 --> 11 | Recruiting --> Terminated; no recruitment on time Active, not recruiting --> Terminated; Inadequate accrual rate
- Enrollment closed, Trial primary completion date: Assessment of Body, Liver and Labile Plasma Iron and Their Association With Outcome and Immunological Recovery in Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) Patients Undergoing Allogeneic Stem Cell Transplantation - ALLIVE (ALLogeneic Iron inVEstigators) Observational Trial (clinicaltrials.gov) - Aug 20, 2015
P=N/A, N=134, Active, not recruiting, Sponsor: GWT-TUD GmbH
Active, not recruiting --> Terminated; Inadequate accrual rate Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2015 --> Dec 2015
- ||| idasanutlin (RG7388) / Roche
Enrollment open, Combination therapy: A Study of RO5503781 as a Single Agent or in Combination With Cytarabine in Participants With Acute Myelogenous Leukemia (clinicaltrials.gov) - Aug 18, 2015
P1, N=125, Recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2015 --> Dec 2015 Active, not recruiting --> Recruiting
- Trial primary completion date, IO biomarker: Immunotherapy for Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Blast Phase Chronic Myelogenous Leukemia (BP CML), and Myelodysplastic Syndrome (MDS) Relapse After Allogeneic Transplantation (clinicaltrials.gov) - Aug 17, 2015
P2, N=15, Active, not recruiting, Sponsor: Emory University
Active, not recruiting --> Recruiting Trial primary completion date: May 2015 --> May 2016
- mycophenolate mofetil / Generic mfg., sirolimus / Generic mfg.
Trial suspension: Inducible Regulatory T Cells (iTregs) in Non-Myeloablative Sibling Donor Peripheral Blood Stem Cell Transplantation (clinicaltrials.gov) - Aug 14, 2015
P1, N=22, Suspended, Sponsor: Masonic Cancer Center, University of Minnesota
Trial primary completion date: May 2015 --> May 2016 Recruiting --> Suspended
- Trial completion, Combination therapy: Bortezomib, Mitoxantrone, Etoposide, and Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Aug 14, 2015
P1, N=3, Completed, Sponsor: Case Comprehensive Cancer Center
Recruiting --> Suspended Active, not recruiting --> Completed
- || Aphexda (motixafortide) / BioLineRx, Gloria Pharma
Trial primary completion date: Phase IIa Study Evaluating Safety and Efficacy of BL-8040 in Relapsed/Refractory AML Patients (clinicaltrials.gov) - Aug 13, 2015
P2a, N=70, Recruiting, Sponsor: BioLineRx, Ltd.
Active, not recruiting --> Completed Trial primary completion date: Jun 2015 --> Oct 2015
- || dovitinib (TKI258) / Novartis, Oncoheroes
Trial primary completion date: SIGNATURE: Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib (clinicaltrials.gov) - Aug 13, 2015
P2, N=80, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Jun 2015 --> Oct 2015 Trial primary completion date: May 2015 --> Dec 2015
- Trial primary completion date: LAMVIRE: Respiratory Viral Infections During Acute Myeloid Leukemia (AML)Chemotherapy Related Aplasia (clinicaltrials.gov) - Aug 13, 2015
P4, N=115, Recruiting, Sponsor: Centre Hospitalier Universitaire, Amiens
Trial primary completion date: May 2015 --> Dec 2015 Trial primary completion date: Oct 2014 --> Dec 2015
- sorafenib / Generic mfg.
Trial primary completion date: Sorafenib Maintenance Therapy for Patients With AML After Allogeneic Stem Cell Transplant (clinicaltrials.gov) - Aug 13, 2015
P1, N=28, Active, not recruiting, Sponsor: Massachusetts General Hospital
Trial primary completion date: Oct 2014 --> Dec 2015 Trial primary completion date: Aug 2014 --> Sep 2015
- Zeltherva (galinpepimut-S) / SELLAS Life Sciences
Trial primary completion date: WT1 Vaccine Treatment of Patients in Remission From Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL) (clinicaltrials.gov) - Aug 13, 2015
P2, N=29, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Trial primary completion date: Aug 2014 --> Sep 2015 Trial primary completion date: Dec 2015 --> Dec 2016
- || Mycamine (micafungin) / Astellas, Noxafil (posaconazole) / Merck (MSD)
Trial primary completion date: Posaconazole Versus Micafungin for Prophylaxis Against Invasive Fungal Infections During Neutropenia in Patients Undergoing Chemotherapy for Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia or Myelodysplastic Syndrome (clinicaltrials.gov) - Aug 13, 2015
P4, N=114, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Trial primary completion date: Dec 2015 --> Dec 2016 Trial primary completion date: Sep 2015 --> Sep 2016
- Trial primary completion date, HEOR: Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer (clinicaltrials.gov) - Aug 13, 2015
P=N/A, N=80, Active, not recruiting, Sponsor: Comprehensive Cancer Center of Wake Forest University
Trial primary completion date: Sep 2015 --> Sep 2016 Trial primary completion date: Oct 2011 --> Feb 2012
- Erivedge (vismodegib) / Roche
Trial termination: A Study of Vismodegib in Patients With Relapsed/Refractory Acute Myelogenous Leukemia and Relapsed Refractory High-Risk Myelodysplastic Syndrome (clinicaltrials.gov) - Aug 13, 2015
P2, N=42, Terminated, Sponsor: Hoffmann-La Roche
Trial primary completion date: Oct 2011 --> Feb 2012 Completed --> Terminated
- Trial suspension, Trial primary completion date: Ultra-Low Dose IL-2 Therapy as GVHD Prophylaxis in Haploidentical Allogeneic Stem Cell Transplantation (clinicaltrials.gov) - Aug 13, 2015
P0, N=40, Suspended, Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Completed --> Terminated Recruiting --> Suspended | Trial primary completion date: Jun 2018 --> Jun 2019
- Mektovi (binimetinib) / Ono Pharma, Pierre Fabre, Pfizer
Trial suspension: MEK Inhibitor MEK162, Idarubicin, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Aug 13, 2015
P1, N=19, Suspended, Sponsor: Bruno C. Medeiros
Recruiting --> Suspended | Trial primary completion date: Jun 2018 --> Jun 2019 Recruiting --> Suspended
- Ninlaro (ixazomib) / Takeda
Trial suspension: Ixazomib (MLN9708) in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Aug 13, 2015
P2, N=16, Suspended, Sponsor: Bruno C. Medeiros
Recruiting --> Suspended Recruiting --> Suspended
- Vyxeos (cytarabine/daunorubicin liposomal formulation) / Jazz
Trial suspension: CPX-351 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome (clinicaltrials.gov) - Aug 13, 2015
P2, N=33, Suspended, Sponsor: Bruno C. Medeiros
Recruiting --> Suspended Recruiting --> Suspended
- Trial suspension: Lenalidomide and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Aug 13, 2015
P1, N=30, Suspended, Sponsor: Stanford University
Recruiting --> Suspended Recruiting --> Suspended
- Zolinza (vorinostat) / Merck (MSD)
Trial suspension, Trial primary completion date: Temozolomide Plus Vorinostat in Relapse/Refractory Acute Myeloid Leukemia (AML) (clinicaltrials.gov) - Aug 13, 2015
P2, N=45, Suspended, Sponsor: Stanford University
Recruiting --> Suspended Recruiting --> Suspended | Trial primary completion date: Apr 2015 --> Jan 2016
- birabresib (OTX015) / Merck (MSD)
Enrollment change, Trial withdrawal, Combination therapy: A Study Assessing tOTX015 in Combination With Azacitidine (AZA) or AZA Single Agent in Patients With Newly-diagnosed Acute Myeloid Leukemia (AML) Not Candidate for Standard Intensive Induction Therapy (SIIT) (clinicaltrials.gov) - Aug 13, 2015
P1/2, N=0, Withdrawn, Sponsor: Oncoethix GmbH
Recruiting --> Suspended | Trial primary completion date: Apr 2015 --> Jan 2016 N=88 --> 0 | Not yet recruiting --> Withdrawn
- fludarabine IV / Generic mfg., busulfan / Generic mfg.
Enrollment closed: Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer (clinicaltrials.gov) - Aug 13, 2015
P1/2, N=225, Active, not recruiting, Sponsor: OHSU Knight Cancer Institute
N=88 --> 0 | Not yet recruiting --> Withdrawn Recruiting --> Active, not recruiting
- busulfan / Generic mfg., etoposide IV / Generic mfg.
Trial completion, Enrollment change: Busulfan and Etoposide Followed by Peripheral Blood Stem Cell Transplant and Low-Dose Aldesleukin in Treating Patients With Acute Myeloid Leukemia (clinicaltrials.gov) - Aug 13, 2015
P2, N=62, Completed, Sponsor: Fred Hutchinson Cancer Research Center
Recruiting --> Active, not recruiting Active, not recruiting --> Completed | N=30 --> 62
- cytarabine / Generic mfg., idarubicin hydrochloride / Generic mfg.
Trial completion: Efficacy and Toxicity of Increasing Doses of Idarubicin, Cytarabine and G-CSF in Acute Myeloid Leukemia (clinicaltrials.gov) - Aug 12, 2015
P2, N=48, Completed, Sponsor: Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias
Active, not recruiting --> Completed | N=30 --> 62 Recruiting --> Completed
- | volasertib (NBL-001) / Oncoheroes, Notable Labs
Trial completion, Trial primary completion date: Volasertib in Japanese Patients With Acute Myeloid Leukemia (AML) (clinicaltrials.gov) - Aug 12, 2015
P1, N=19, Completed, Sponsor: Boehringer Ingelheim
Recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Apr 2014 --> May 2015
- Trial completion, Post-transplantation: Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies (clinicaltrials.gov) - Aug 12, 2015
P2, N=44, Completed, Sponsor: Fred Hutchinson Cancer Research Center
Active, not recruiting --> Completed | Trial primary completion date: Apr 2014 --> May 2015 Active, not recruiting --> Completed
- Onureg (azacitidine oral) / BMS
Enrollment change, Trial termination, Trial primary completion date: Phase 1 Study of CC-486 in Japanese Subjects With Hematological Neoplasms (clinicaltrials.gov) - Aug 11, 2015
P1, N=2, Terminated, Sponsor: Celgene Corporation
Active, not recruiting --> Completed N=30 --> 2 | Recruiting --> Terminated | Trial primary completion date: Mar 2017 --> Jul 2015; Due to Slow Accrual study was terminated.
- || idasanutlin (RG7388) / Roche
Enrollment closed, Combination therapy: A Study of RO5503781 as a Single Agent or in Combination With Cytarabine in Participants With Acute Myelogenous Leukemia (clinicaltrials.gov) - Aug 11, 2015
P1, N=115, Active, not recruiting, Sponsor: Hoffmann-La Roche
N=30 --> 2 | Recruiting --> Terminated | Trial primary completion date: Mar 2017 --> Jul 2015; Due to Slow Accrual study was terminated. Recruiting --> Active, not recruiting
- | Zarnestra (tipifarnib) / Kura Oncology
Trial completion: Tipifarnib, Cytarabine, and Daunorubicin in Treating Older Patients With Acute Myeloid Leukemia (clinicaltrials.gov) - Aug 9, 2015
P1, N=24, Completed, Sponsor: University Health Network, Toronto
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- fludarabine IV / Generic mfg., busulfan / Generic mfg.
Trial primary completion date: Fludarabine and Busulfan Followed by Allogeneic Stem Cell Transplant in Treating Older Patients With Acute Myeloid Leukemia in First Complete Remission (clinicaltrials.gov) - Jul 21, 2015
P2, N=61, Active, not recruiting, Sponsor: Alliance for Clinical Trials in Oncology
Active, not recruiting --> Completed Trial primary completion date: Jan 2014 --> Dec 2016